Treatment Options for Protease Inhibitor-exposed Children.

Trial Profile

Treatment Options for Protease Inhibitor-exposed Children.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Abacavir (Primary) ; Efavirenz (Primary) ; Lopinavir/ritonavir; Stavudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NEVEREST-3; NEVEREST-III
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2017 Results assessing long term outcomes of the trial, published in the Clinical Infectious Diseases
    • 16 Feb 2017 Results of cost effectiveness of preemptive switch to efevirenz presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top